Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Lambert

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 PatientsFlorian Herms, Jerome Lambert, Jean-Jacques Grob, et al.
Blood Advances|October 9, 2021
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AMLJuliette Lambert, Jerome Lambert, Xavier Thomas, et al.
British Journal of Haematology|November 13, 2023
Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational studyLaurent Garderet, Hafida Ouldjeriouat, Mohamed-Amine Bekadja, et al.
Haematologica|October 16, 2012
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemiaFlorence Nguyen-Khac, Jerome Lambert, Elise Chapiro, et al.
Blood|March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease ResultsJill Corre, Laure Vincent, Philippe Moreau, et al.
Blood Advances|September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2022
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell CarcinomaAndrey A Yurchenko, Oltin T Pop, Meriem Ighilahriz, et al.
Journal of Neurointerventional Surgery|August 27, 2025
Glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction: GREEN studyMikaël Mazighi, Jerome Lambert, Benjamin Gory, et al.
Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Nature Medicine|June 3, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Cyrille Hulin, Jerome Lambert, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 PatientsFlorian Herms, Jerome Lambert, Jean-Jacques Grob, et al.
Blood Advances|October 9, 2021
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AMLJuliette Lambert, Jerome Lambert, Xavier Thomas, et al.
British Journal of Haematology|November 13, 2023
Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational studyLaurent Garderet, Hafida Ouldjeriouat, Mohamed-Amine Bekadja, et al.
Haematologica|October 16, 2012
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemiaFlorence Nguyen-Khac, Jerome Lambert, Elise Chapiro, et al.
Blood|March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease ResultsJill Corre, Laure Vincent, Philippe Moreau, et al.
Blood Advances|September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2022
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell CarcinomaAndrey A Yurchenko, Oltin T Pop, Meriem Ighilahriz, et al.
Journal of Neurointerventional Surgery|August 27, 2025
Glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction: GREEN studyMikaël Mazighi, Jerome Lambert, Benjamin Gory, et al.
Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Nature Medicine|June 3, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Cyrille Hulin, Jerome Lambert, et al.
Pageof 3